NY-J.P.-MORGAN
6.6.2019 13:32:03 CEST | Business Wire | Press release
J.P. Morgan’s focus and investment in global e-commerce payments is paying off with top rankings from The Nilson Report, the independent payments industry source:
| #1 e-commerce provider in Europe (by web transaction volume)1 |
| #4 merchant acquirer in Europe (by overall transaction volume)2 |
According to The Nilson Report, J.P. Morgan processes almost 30% of all web transactions in Europe,3 ranging from multinationals headquartered in Europe and the U.S. to local European businesses with global ambitions. E-commerce in Europe is large and growing and is expected to exceed EURO 851.03 billion in spend by 2021,4 according to Edgar, Dunn & Company.
“E-commerce has created a seismic shift in the way consumers shop and pay for their purchases and this trend is evidenced by our growth from the sixth to the fourth largest merchant acquirer in Europe,” said Catherine Moore, President of Europe for J.P. Morgan Merchant Services. “As a pure-play e-commerce acquirer in Europe, we help merchants optimise their overall cost of payments and maximise business profitability.”
E-commerce merchants are not only benefitting from significant growth in Europe, but also dealing with complexities of compliance with the European Union’s Second Payment Services Directive (PSD2) and Strong Customer Authentication (SCA) coming into force this September.
“The key is finding the right balance between protecting the consumer and providing a seamless payments experience that helps merchants drive down fraud levels,” Moore said. “We are PSD2-ready and collaborating closely with all industry stakeholders to help make this game-changing directive a success both for the industry and consumers.”
J.P. Morgan was also recently named the #1 merchant acquirer in the U.S.5 (by purchase volume) by The Nilson Report and #1 merchant acquirer in the U.S.6 by The Strawhecker Group in 2019.
Learn more about J.P. Morgan’s global payments offerings, PSD2/SCA or request a consultation by visiting https://www.jpmorgan.com/europe/merchant-services .
About J.P. Morgan
J.P. Morgan offers a full suite of payments services to enable a seamless connection across the payments continuum for clients. We bring our consultative expertise, data-driven insights, and local service around the globe to provide a more unified view of payables, receivables and cash management. Merchant Services is the payment acceptance and merchant acquiring business of JPMorgan Chase & Co. (NYSE: JPM) – a global financial services firm with assets of $2.6 trillion and operations worldwide.7 According to The Nilson Report, it is also the top merchant acquirer of e-commerce transactions in Europe.8
| 1 The Nilson Report #1153, May 2019 | ||||||||
| 2 The Nilson Report #1153, May 2019 | ||||||||
| 3 The Nilson Report #1153, May 2019 | ||||||||
| 4 Global Payments Depository, Edgar, Dunn & Company, 2018 | ||||||||
| 5 The Nilson Report #1149, March 2019 | ||||||||
| 6 Directory of U.S. Merchant Acquirers (TSG Top 300), The Strawhecker Group, March 2019 | ||||||||
| 7 JPMorgan Chase & Co. Q4 2018 Earnings Report 2018 | ||||||||
| 8 The Nilson Report #1153, May 2019 | ||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005205/en/
Contact:
Media Contacts Allison Tobin Reed, Vice President, Communications, J.P. Morgan Email: allison.reed@jpmchase.com
Ludo Baynham-Herd, Associate Director, FleishmanHillard Fishburn Email: ludo.baynham-herd@fhflondon.co.uk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom